Shopping Cart 0
Cart Subtotal
USD 0

Idera Pharmaceuticals Inc (IDRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of drugs for the treatment of cancer and rare diseases. It develops DNA and RNA based drug candidates aimed at toll-like receptors (TLR) for the treatment of infectious diseases and for use as vaccine adjuvants. The company initiated a research program employing its gene silencing technologies to suppress the production of proteins associated with diseases by targeting RNA. It designs and formulates proprietary TLR agonists and antagonists to modulate immune responses. The lead products in the pipeline are IMO-2125, IMO-8400, IMO-9200, and antagonists of TLRs 7, 8, and 9 for the treatment of lupus. Idera is headquartered in Massachusetts, the US.

Idera Pharmaceuticals Inc (IDRA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Idera Pharma Enters into Agreement with Pillar Partners Foundation 12

Idera Pharma Enters into Research Agreement with University of Texas 13

Licensing Agreements 14

Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 14

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 15

Equity Offering 16

Idera Pharma Prices Public Offering of Shares for USD50 Million 16

Idera Pharma Raises USD52.5 Million in Public Offering of Shares 18

Idera Pharma Raises USD86.3 Million in Public Offering of Shares 20

Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For USD 40 Million 22

Idera Pharma Completes Public Offering Of Shares For USD 27.7 Million 23

Idera Pharma Completes Public Offering Of Shares And Warrants For USD 16.5 Million 25

Idera Pharma Completes Private Placement Of Preferred Shares For USD 7 Million 27

Idera Pharmaceuticals Inc-Key Competitors 28

Idera Pharmaceuticals Inc-Key Employees 29

Idera Pharmaceuticals Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 02, 2018: Idera Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 31

May 09, 2018: Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 34

Mar 07, 2018: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 36

Nov 06, 2017: Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38

Aug 07, 2017: Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results 41

May 04, 2017: Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 44

Mar 15, 2017: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update 47

Corporate Communications 50

Sep 18, 2018: Idera Pharmaceuticals names Howard Pien as Board Director 50

Apr 23, 2018: Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors 51

Oct 24, 2017: Idera Pharmaceuticals Provides Corporate Governance Update 52

Apr 18, 2017: Idera Pharmaceuticals Announces Organizational Update 53

Legal and Regulatory 54

Mar 23, 2018: Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals 54

Product News 55

11/09/2017: Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC) 55

04/11/2017: Idera Pharmaceuticals Advances Investigational Treatment-Intratumoral IMO-2125 in Combination with Ipilimumab-for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma 57

02/06/2017: Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development 59

Product Approvals 60

Nov 29, 2017: U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals' IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma 60

Jun 22, 2017: Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma 61

Clinical Trials 63

Jun 04, 2018: Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 63

Apr 26, 2018: Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting 65

Apr 17, 2018: Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting 67

Mar 01, 2018: Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) 68

Sep 10, 2017: Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy 69

Sep 08, 2017: Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory 71

Apr 05, 2017: Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting 72

Feb 24, 2017: Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 74

Other Significant Developments 75

Jul 16, 2018: Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook 75

Jan 05, 2018: Idera Pharmaceuticals Provides 2018 Update and Outlook 77

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Idera Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Idera Pharma Enters into Agreement with Pillar Partners Foundation 12

Idera Pharma Enters into Research Agreement with University of Texas 13

Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 14

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 15

Idera Pharma Prices Public Offering of Shares for USD50 Million 16

Idera Pharma Raises USD52.5 Million in Public Offering of Shares 18

Idera Pharma Raises USD86.3 Million in Public Offering of Shares 20

Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For USD 40 Million 22

Idera Pharma Completes Public Offering Of Shares For USD 27.7 Million 23

Idera Pharma Completes Public Offering Of Shares And Warrants For USD 16.5 Million 25

Idera Pharma Completes Private Placement Of Preferred Shares For USD 7 Million 27

Idera Pharmaceuticals Inc, Key Competitors 28

Idera Pharmaceuticals Inc, Key Employees 29

Idera Pharmaceuticals Inc, Other Locations 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Idera Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Idera Pharmaceuticals Inc. (Idera) is a clinical stage biopharmaceutical company, which focuses on the discovery, development and commercialization of drugs for the treatment of cancer and rare diseases. It develops DNA and RNA based drug candidates aimed at toll-like receptors (TLR) for the treatment of infectious diseases and for use as vaccine adjuvants. The company initiated a research program employing its gene silencing technologies to suppress the production of proteins associated with diseases by targeting RNA. It designs and formulates proprietary TLR agonists and antagonists to modulate immune responses. The lead products in the pipeline are IMO-2125, IMO-8400, IMO-9200, and antagonists of TLRs 7, 8, and 9 for the treatment of lupus. Idera is headquartered in Massachusetts, the US.

Idera Pharmaceuticals Inc (IDRA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Idera Pharma Enters into Agreement with Pillar Partners Foundation 12

Idera Pharma Enters into Research Agreement with University of Texas 13

Licensing Agreements 14

Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 14

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 15

Equity Offering 16

Idera Pharma Prices Public Offering of Shares for USD50 Million 16

Idera Pharma Raises USD52.5 Million in Public Offering of Shares 18

Idera Pharma Raises USD86.3 Million in Public Offering of Shares 20

Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For USD 40 Million 22

Idera Pharma Completes Public Offering Of Shares For USD 27.7 Million 23

Idera Pharma Completes Public Offering Of Shares And Warrants For USD 16.5 Million 25

Idera Pharma Completes Private Placement Of Preferred Shares For USD 7 Million 27

Idera Pharmaceuticals Inc-Key Competitors 28

Idera Pharmaceuticals Inc-Key Employees 29

Idera Pharmaceuticals Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 02, 2018: Idera Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 31

May 09, 2018: Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 34

Mar 07, 2018: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 36

Nov 06, 2017: Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38

Aug 07, 2017: Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results 41

May 04, 2017: Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 44

Mar 15, 2017: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update 47

Corporate Communications 50

Sep 18, 2018: Idera Pharmaceuticals names Howard Pien as Board Director 50

Apr 23, 2018: Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors 51

Oct 24, 2017: Idera Pharmaceuticals Provides Corporate Governance Update 52

Apr 18, 2017: Idera Pharmaceuticals Announces Organizational Update 53

Legal and Regulatory 54

Mar 23, 2018: Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals 54

Product News 55

11/09/2017: Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC) 55

04/11/2017: Idera Pharmaceuticals Advances Investigational Treatment-Intratumoral IMO-2125 in Combination with Ipilimumab-for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma 57

02/06/2017: Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development 59

Product Approvals 60

Nov 29, 2017: U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals' IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma 60

Jun 22, 2017: Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma 61

Clinical Trials 63

Jun 04, 2018: Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 63

Apr 26, 2018: Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting 65

Apr 17, 2018: Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting 67

Mar 01, 2018: Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) 68

Sep 10, 2017: Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy 69

Sep 08, 2017: Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory 71

Apr 05, 2017: Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting 72

Feb 24, 2017: Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 74

Other Significant Developments 75

Jul 16, 2018: Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook 75

Jan 05, 2018: Idera Pharmaceuticals Provides 2018 Update and Outlook 77

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Idera Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Idera Pharma Enters into Agreement with Pillar Partners Foundation 12

Idera Pharma Enters into Research Agreement with University of Texas 13

Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 14

GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 15

Idera Pharma Prices Public Offering of Shares for USD50 Million 16

Idera Pharma Raises USD52.5 Million in Public Offering of Shares 18

Idera Pharma Raises USD86.3 Million in Public Offering of Shares 20

Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For USD 40 Million 22

Idera Pharma Completes Public Offering Of Shares For USD 27.7 Million 23

Idera Pharma Completes Public Offering Of Shares And Warrants For USD 16.5 Million 25

Idera Pharma Completes Private Placement Of Preferred Shares For USD 7 Million 27

Idera Pharmaceuticals Inc, Key Competitors 28

Idera Pharmaceuticals Inc, Key Employees 29

Idera Pharmaceuticals Inc, Other Locations 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Idera Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.